Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New lens injector aims to sharpen cataract surgery outcomes

NCT ID NCT07288086

Disease control Sponsor: Istanbul University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new preloaded lens delivery system for cataract surgery in 200 adults aged 40 and older. The device is designed to simplify the procedure and reduce handling of the lens. Researchers will measure how well patients see after surgery and how surgeons rate the system's ease of use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Preloaded intraocular lens delivery system (device)
What this could lead to
If successful, this could make cataract surgery faster and more consistent, with better visual results for patients.
What could go wrong
This is a small, early-stage study focused on device performance, not a cure. Results may not apply to all patients or lens types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

200 people

The number who actually took part.

Started

May 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults of either sex. Age 40 years or older. Willing and able to provide written informed consent and comply with planned study visits and procedures. Healthy ocular status, with no ocular pathology other than cataract and mild refractive error. Potential visual acuity of 20/32 (0.2 logMAR) or better in both eyes. Presence of regular corneal astigmatism suitable for treatment with the study device. Candidates for uncomplicated cataract surgery using the study device. Exclusion Criteria: * Irregular corneal astigmatism (e.g., keratoconus). Corneal pathology (e.g., scar, dystrophy, pterygium, moderate to severe dry eye). Monocular conditions (e.g., amblyopia). Previous corneal surgery, including radial keratotomy, corneal refractive surgery, corneal transplantation, DSAEK, or lamellar keratoplasty. Previous anterior or posterior segment surgery (e.g., vitrectomy, laser iridotomy). Diabetic retinopathy. Macular pathology (e.g., age-related macular degeneration \[ARMD\], epiretinal membrane \[ERM\]). History of retinal detachment. Surgical complications that may affect study outcomes, such as: Decentration due to capsulorhexis issues Improper lens placement Inadequate or missing postoperative capsular support Posterior capsular rupture Vitreous loss Iris damage (tear, rupture, etc.) Acute or chronic ocular diseases known to affect visual acuity or study outcomes (e.g., immunosuppressed state, connective tissue disease, clinically significant atopic disease, diabetes, or other systemic or ocular conditions). Participation in any investigational drug or device study within 30 days prior to study start, or ongoing participation in another study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cataract are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cataract lens disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cataract surgery Intraocular lens

Contacts and locations

Locations

  • Istanbul University Istanbul Medical Faculty Ophthalmology Department

    Istanbul, Fatih, 34250, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.